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Staphylococcal enterotoxins are 23- to 29-kDa
polypeptides in the bacterial superantigen protein family.
Clinical symptoms from intoxication with staphylococcal
enterotoxins vary by exposure route. Ingestion results in
gastrointestinal symptoms, and inhalation results in fever
as well as pulmonary and gastrointestinal symptoms.
Review of occupational exposures at the U.S. Army
Medical Research Institute of Infectious Diseases from
1989 to 2002 showed that three laboratory workers had
symptoms after ocular exposure to staphylococcal entero-
toxin B (SEB). Conjunctivitis with localized cutaneous
swelling occurred in three persons within 1 to 6 hours after
exposure to SEB; two of these persons also had gastroin-
testinal symptoms, which suggests that such symptoms
occurred as a result of exposure by an indirect cutaneous
or ocular route. Ocular exposures from SEB resulting in
conjunctivitis and localized swelling have not previously
been reported. Symptoms from these patients and review
of clinical symptoms of 16 laboratory-acquired inhalational
SEB intoxications may help healthcare workers evaluate
and identify SEB exposures in laboratory personnel at risk.
S
taphylococcal enterotoxins are 23- to 29-kDa polypep-
tides in the bacterial superantigen protein family that
act by cross-linking HLA-DR or DQ molecules and T-cell
receptors. This cross-linking results in potentially patho-
logic levels of proinflammatory cytokines, such as tumor
necrosis factor α, interleukin 2, and interferon-γ (1,2).
Therefore, symptoms of mild exposure are anticipated to
resemble T-cell–mediated recall responses, similar to a
Mantoux skin test.
Staphylococcal enterotoxin B (SEB) is one of at least 15
antigenically distinct enterotoxin proteins (3,4). Clinical
symptoms depend on the route of exposure. After inhala-
tion of SEB, clinical features include fever, respiratory
complaints (cough, dyspnea, and retrosternal discomfort or
chest pain), and gastrointestinal symptoms; severe intoxi-
cation results in pulmonary edema, adult respiratory dis-
tress syndrome, shock, and death (5,6). Ingesting SEB may
cause food poisoning within 1 to 6 hours of exposure, man-
ifested as acute salivation, nausea, and vomiting, followed
by abdominal cramps and diarrhea (7,8). As ingesting SEB
does not typically result in pulmonary symptoms, gastroin-
testinal symptoms observed from inhalational intoxication
are postulated to result from secondary oral ingestion of
SEB concomitant with the inhalational exposure. 
One laboratory incident that resulted in nine cases of
inhalational intoxication to SEB and several other out-
breaks of food poisoning from ingesting staphylococcal
enterotoxins have been reported in the literature (5).
Symptoms occurring after ocular exposure and localized
cutaneous swelling or conjunctivitis from staphylococcal
enterotoxins have not been reported. We report three cases
of purulent conjunctivitis with localized facial swelling
that occurred after ocular exposure to SEB in the laborato-
ry. Two of the three patients also complained of gastroin-
testinal symptoms. The symptoms in these three
mucocutaneous-acquired cases, and summary of symp-
toms from 16 laboratory-acquired inhalational intoxica-
tions with SEB, may help define the clinical spectrum that
might be expected after SEB exposures. The full spectrum
of clinical signs and symptoms of intoxication with SEB is
important to healthcare workers evaluating persons with
potential exposures to these agents, including in the con-
text of bioterrorism. This discussion is also relevant to mil-
itary practitioners, since SEB has been previously
developed as an incapacitating biowarfare agent. 
Methods
During a review of occupational exposures evaluated in
the Special Immunizations Clinic at the U.S. Army
Medical Research Institute of Infectious Diseases from
1989 to 2002, clinical evaluations of three laboratory
workers with symptoms of conjunctivitis and localized
swelling after exposure to SEB were identified. Patient
records and occupational exposure summaries were
reviewed. Additionally, clinical histories of 16 persons
with symptoms after inhalational intoxication with SEB,
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and occupational exposure reports, were reviewed to sum-
marize the spectrum of symptoms resulting from inhala-
tional exposure to SEB.
Results
Patient 1
While injecting SEB into the endotracheal tube of a
rabbit, a 22-year-old male laboratory worker sprayed
approximately 150 µg of SEB onto his right glove.
Sometime later, he recalled scratching his nose and the
area adjacent to his right eye. Three hours after the inci-
dent, he noted irritation, pruritus, and a yellow discharge
from his right eye. Nine to 12 hours after the incident, he
had onset of gastrointestinal symptoms (nausea, abdominal
cramps, and loose stools [approximately eight nonbloody
loose stools over the next 8 hours]), nasal congestion, post-
nasal drip, and a self-reported fever. The following morn-
ing (approximately 18 h after the incident), he awoke with
profound swelling of the right lower eyelid and passed
three more loose stools. He did not have headache, chills,
vomiting, cough, dyspnea, chest discomfort, or myalgias. 
Physical examination was remarkable for diffuse
hyperemia of the eye, mildly edematous conjunctiva infe-
riorly, and edema of the lower lid. The patient was given
loperamide for control of diarrhea and sulfacetamide oph-
thalmic ointment to the right eye four times daily.
Gastrointestinal symptoms resolved within 2 days, and the
ocular symptoms, nasal congestion, postnasal drip, and
febrile symptoms resolved within 4 days. The laboratory
worker discontinued loperamide at day 2 and sulfac-
etamide ointment at day 4.
The amount of SEB in the spray was estimated to be
<150 µg. However, the amount of SEB exposure to the
right eye was even less, since only a portion of the solution
was sprayed onto his hand and rubbed into his eye. The
worker was wearing a Tyvek suit (DuPont, Wilmington,
DE) and gloves at the time of the exposure but no goggles
or respirator. As a consequence, safety measures were
modified to recommend only Leur-Lock syringes (Baxter
International Inc., Deerfield, IL) and to require eye protec-
tion and surgical masks while working with the toxin.
Patient 2
During the reconstitution of SEB within a biosafety
cabinet, a 20-year-old laboratory worker injected the con-
tents of a syringe containing 500 µg of SEB into a sealed
vial and was exposed when the solution in the vial came
under pressure. Approximately 100 µL of SEB in solution
foamed from the sealed vial. A small portion of the solu-
tion came into contact with the fourth finger on her left
hand. She was not wearing gloves. She immediately
washed the site with soap and water for 15 seconds and
rinsed the soap from her hands. Before she dried her hands,
she unconsciously rubbed her left eye with her left hand. 
Within 6 to 9 hours of exposure, she had onset of a thick
mucous discharge from her left eye, a swollen eye lid, nau-
sea, and loose stools. She had no fever, headache, cough,
dyspnea, chest discomfort, vomiting, or myalgias. She was
seen at a local emergency room that evening, and was
given gentamicin eye drops with a presumed diagnosis of
“pink eye” and phenergan for nausea. She was told to
remove her contact lenses. The following morning, she
was seen in the Special Immunizations Clinic for evalua-
tion for a potential occupational exposure, after reporting
to her supervisor that her symptoms might be related to
contact with SEB the previous day. Physical examination
showed swelling of the left eyelid and discharge from the
eye. The discharge was initially described as “long
threads” and was subsequently noted to have a yellow
color and tear-like appearance. Her symptoms of nausea
and diarrhea continued; symptoms exacerbated with food
intake. The gastrointestinal symptoms resolved in 3 days,
and the ocular symptoms in 5 days. 
The estimated syringe loss was 500 µg, but the amount
of exposure was estimated to be <50 µg, since only a small
portion of the solution was in contact with her hand.
Because the toxin is extremely water soluble, the immedi-
ate washing of the hands should have effectively removed
a large amount of the toxin. 
Patient 3
One hour after cleaning a dime-size amount of liquid,
likely to have been SEB, found outside a biosafety cabinet,
a 23-year-old laboratory technician noted bilateral eye irri-
tation, conjunctival erythema, and an excessive yellow
ocular discharge that continued throughout the day. She
awoke the next morning (day 2) with facial swelling, per-
sistent ocular symptoms, and a subconjunctival hemor-
rhage (possibly resulting from SEB transfer from hand to
eye). She medicated herself with diphenhydramine and
brompheniramine and noted improvement in her symp-
toms the following day (day 3). 
On the morning of day 3, she visited the Special
Immunizations Clinic for evaluation. At that time, the
facial swelling had resolved, and the ocular symptoms had
nearly resolved. She had no fever, headache, cough, dysp-
nea, chest discomfort, nausea, vomiting, diarrhea, or myal-
gias. Physical examination was remarkable for bilateral
conjunctival injection and a 5-mm x 2-mm subconjuncti-
val hemorrhage at the inferolateral margin of the right iris.
Complete blood count and erythrocyte sedimentation rate
were within normal limits. She was seen by her private
ophthalmologist later that day, who recommended no spe-
cific treatment. Her symptoms resolved on day 4.
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Staphylococcal Enterotoxin BSubsequently, this patient had mild ocular erythema
and irritation (no facial swelling or conjunctivitis) while in
the laboratory where SEB studies were ongoing. These
symptoms resolved immediately after she left the room,
which suggests hypersensitivity. She was advised to avoid
entering the laboratory when SEB was being used or con-
sider prophylactic use of antihistamines to control symp-
toms.
Inhalational Cases
Three historical events that occurred during the now
disbanded U.S. offensive biologic warfare program result-
ed in inhalational exposures to SEB and subsequent intox-
ication. The spectrum of symptoms occurring in the three
events is summarized in the Table.
In early 1963, two persons were exposed to SEB as a
result of a ruptured hose that contained a crude filtrate of
SEB under moderate pressure. Acute asthmatic bronchitis
developed in one of these persons within a few hours of
exposure. Fever, headache, myalgias, nonproductive
cough, dyspnea, nausea, vomiting, and diarrhea developed
in both persons, with maximal symptoms at 12 hours and
resolution of symptoms by day 3. 
In June 1963, five of seven persons became ill within
24 hours of exposure to a highly purified SEB aerosol after
a dose-titration experiment in monkeys using a Henderson
apparatus for administration of the aerosol; four of the per-
sons required hospitalization (9). The source was suspect-
ed to be residual SEB from fur on the monkeys’ heads,
which had not been wiped after the exposure to SEB.
Fever, cough, sternal tightness, anorexia, nausea, and vom-
iting were prominent features of intoxication; these signs
and symptoms started within a few hours to as late as 24
hours after exposure.  
The third event occurred in August 1964, when a leak
in tubes carrying aerosolized SEB to test monkeys result-
ed in exposure of 15 persons. Ten persons became sympto-
matic, and 9 of them were hospitalized (5).
Onset of symptoms from inhalational intoxication was
within 1–1/2 hours to 24 hours of exposure (most within
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Table. Signs and symptoms of inhalational intoxication to staphylococcal enterotoxin B 
Signs and symptoms 
Event 1
a (1963) 
N = 2 
Event 2
b (1963) 
N = 4 
Event 3 (1964) 
N = 10  Total (%) 
Generalized        
Fever 2  4  9  15/16  (93.7) 
Chills 2  2  9  13/16  (81.3) 
Headache 2  2  9  13/16  (81.3) 
Myalgia 2  1  8  11/16  (68.7) 
Fatigue ND
c 2 8  10/14  (71.4) 
Malaise ND  2  7  9/14  (64.3) 
Lower respiratory         
Cough 2  3  10  15/16  (93.7) 
Dyspnea 2  2  4  8/16  (50.0) 
Retrosternal or chest pain  ND  3  5  8/14 (57.1) 
Wheezing 1  0  1  2/16  (12.5) 
Gastrointestinal        
Nausea 2  4  6  12/16  (75.0) 
Vomiting 2  3  4  9/16  (56.3) 
Anorexia 2  2  5  9/16  (56.3) 
Abdominal cramps  ND  1  2  3/14 (21.4) 
Diarrhea
d 2 0  0  2/16  (12.5) 
Gas ND  0  1  1/14  (7.1) 
Hepatitis 0  0  1  1/14  (7.1) 
Upper respiratory         
Pharyngeal injection  ND  2  3  5/14 (35.7) 
Rhinorrhea, postnasal  drip, or sinus congestion  ND  2  2  4/14 (28.6) 
Sore throat  ND  1  2  3/14 (21.4) 
Otitis ND  1  1  2/14  (14.3) 
Hoarseness ND  0  1  1/14  (7.1) 
Other        
Conjunctival injection  ND  2  2  4/14 (28.6) 
Burning eyes  ND  0  1  1/14 (7.1) 
Flushed face  ND  1  0  1/14 (7.1) 
aOnly occupational summary reports reviewed (medical records not available). 
bNo records available on the one nonhospitalized symptomatic person. 
cND, no data. 
dLoose stools noted in one person in the second and the third events. 12 hours of exposure), and the duration of symptoms was
generally 3–5 days. In addition to the previously reported
and commonly observed symptoms of fever, headache,
myalgias, pulmonary symptoms, and gastrointestinal
symptoms, fatigue and malaise were observed in most per-
sons (Table). While diarrhea was reported in a few cases,
it was not a prominent finding with SEB intoxication by
inhalation. Conjunctival injection, previously reported in
the literature, was noted only in four persons.
Newly reported symptoms include upper respiratory
symptoms (e.g., sore throat, profuse postnasal drip, sinus
congestion, rhinorrhea, coryza, and hoarseness).
Pharyngeal injection (five persons) and injected tympanic
membranes (two persons) were observed; neither had been
previously reported in the literature. 
Discussion
Outside the context of food poisoning, few physicians
would be expected to have experience evaluating persons
with SEB intoxication. However, an increase in laboratory
exposures and intoxications with staphylococcal entero-
toxins can be expected as additional institutions begin
work with them as a result of increased funding for biode-
fense research. Symptoms of conjunctivitis with periocular
or facial swelling, acquired by ocular or cutaneous expo-
sure routes, have not been previously reported in the liter-
ature. A historical occupational health Department of
Defense report suggests that conjunctivitis and upper res-
piratory tract symptoms resulting from exposures to
staphylococcal enterotoxins were recognized during the
time of the U.S. offensive biological warfare program from
1945 to 1969 (10). Therefore, documenting the full clini-
cal spectrum of intoxications with staphylococcal entero-
toxins is necessary to educate healthcare workers and
safety officers to enable them to identify workers at risk
and prevent exposures to staphylococcal enterotoxins. 
Clinical symptoms from SEB may vary and are depend-
ent on the dosage and route of exposure (5). While inhal-
ing SEB may result in fever, pulmonary, and
gastrointestinal symptoms; ingestion of staphylococcal
enterotoxins generally results mainly with gastrointestinal
symptoms. The gastrointestinal symptoms noted in two
persons with ocular or percutaneous exposures (or both)
suggest that gastrointestinal symptoms from SEB may
occur by a nonoral route, although transmission of SEB to
the gastrointestinal tract via the lacrimal duct cannot be
entirely excluded. Also, recurring symptoms of ocular irri-
tation and erythema when in the presence of SEB, and
immediate resolution of symptoms when no longer in an
SEB area, suggests a possible hypersensitivity to SEB. 
The pathophysiology of symptoms from staphylococcal
enterotoxins, however, is not fully understood.
Staphylococcal enterotoxins are superantigens that act by
cross-linking HLA-DR or DQ molecules and T-cell recep-
tors, resulting in high levels of inflammatory cytokines
such as interleukin 2, interferon-γ, and tumor necrosis fac-
tor (1). Staphylococcal enterotoxins resist inactivation by
gastrointestinal proteases; oral dosages as low as 5–20 µg
induce emesis in nonhuman primates (4,8). However, non-
gastrointestinal routes such as intravenous administration
of SEB (higher dosages of 20 to 500 µg) also induced eme-
sis in nonhuman primates.
High levels of cytokines alone may cause symptoms
similar to SEB intoxication. Cancer patients, given high
doses intravenously of the cytokine interleukin-2, have
symptoms of fever, malaise, nausea, vomiting, and diar-
rhea, similar to SE food poisoning (7). Also, intravenous
OKT3, a monoclonal antibody used as an immunosuppres-
sant in transplant patients (it binds to Tlymphocytes, result-
ing in early activation of T cells, cytokine release, and
subsequent blocking of T-cell functions), has a side effect
profile similar to that of SEB—high fever, gastrointestinal
symptoms, arthralgias, and pulmonary symptoms (11).
The mechanism of emesis also has been postulated to
be related to the stimulation of mast cells and the subse-
quent release of cysteinyl leukotrienes and histamine (12).
L4 171883, a selective inhibitor of LTD4/LTEF receptors,
completely eliminated the emetic response and immediate
type skin reactions (skin reactions associated with degran-
ulation of cutaneous mast cells) to SEB. Inhibition of
prostaglandins by indomethicin or pretreatment with a
dual lipoxygenase and cyclo-oxygenase inhibitor (BW
755C) did not prevent emesis or immediate type skin reac-
tions. After degranulation of mast cells, impulses are sent
through the vagus and sympathetic nerves to the medullary
center, which results in emesis. Severing of the vagus and
sympathetic nerves inhibits the emesis response (13).
The mechanism of diarrhea is even less well under-
stood, although it is not by means of activation of adeny-
late cyclase (5). Histopathologic findings with
staphylococcal food poisoning are minimal; they mainly
show polymorphonuclear cell infiltrates in the epithelium
and lamina propria of the stomach and proximal small
intestine (7,8).
SEB intoxication is diagnosed by clinical symptoms
and a history of potential exposure to SEB. Definitive
diagnosis of inhalational exposure can be made by nasal
swabs and induced respiratory secretions for toxin assays,
blood and urine for immunoassay, and acute- and conva-
lescent-phase serum, but these tests are not readily avail-
able and not reliable for low-dose exposures. While
inhalational intoxication with SEB is generally associated
with leukocytosis and a mildly elevated erythrocyte sedi-
mentation rate, these findings are nonspecific. Chest x-ray
findings of increased interstitial markings, atelectesis,
overt pulmonary edema, or acute respiratory distress
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tional intoxications of SEB (5). Potential changes in serum
antibody titers, although relevant, have not been examined.
Toxic and lethal doses of SEB vary greatly between
animal species, mostly because of differences in receptor-
binding affinities, and also vary depending on the route of
exposure (14). In humans, the estimated 50% lethal dose
(LD50) is 0.02 µg/kg and 50% effective dose (ED50) is
0.0004 µg/kg by aerosolized exposure (14). No data exist
on the LD50 and ED50 in humans by other routes of expo-
sure. The ED50 is estimated to be 0.03–0.26 µg/kg in mon-
keys and 12–40 µg in chimpanzees, by intraperitoneal or
intravenous challenge. The extrapolation of the estimated
values of ED50 of nonhuman primates to humans would
suggest that 2 µg versus 840 µg of SEB would be needed
to cause symptoms in a 70-kg person through the ocular or
cutaneous route. Occurrence of symptoms in two persons
after exposure to dosages of SEB <50 µg provides support
that the lower ED50 value in monkeys may also apply to
humans.
During the offensive biologic warfare program, a con-
tractor report addressing the efficacy of biosafety cabinets
noted toxic reactions in persons performing SEB purifica-
tion studies on open laboratory benches (10). The follow-
ing symptoms were noted in six persons: conjunctivitis,
nondescript chemical irritation of one eye, general skin
reaction, severe facial skin reaction, dermatitis, and cold
symptoms. Additionally, symptoms mainly of conjunctivi-
tis and acute pharyngitis, but also including vomiting and
diarrhea in two cases, were observed in 23 persons wear-
ing surgical masks or face shields while working with
SEB. Persons working with SEB within a biosafety cabi-
net had no symptoms. 
As exposure to low dosages of SEB can produce symp-
toms, these recently reported symptoms have importance
both to safety officers and healthcare workers evaluating
laboratory workers at risk with potential exposures to
staphylococcal enterotoxins. SEB intoxication can mimic
an infectious process. The initial diagnosis of the first per-
son who sought medical evaluation in the June 1963 inci-
dent was pneumococcal pneumonia; symptoms included
acute onset of fever, chills, productive cough, chest pain,
and dyspnea. The patient was started on penicillin, which
was discontinued after his co-workers exhibited similar
symptoms, a finding that supported the diagnosis of SEB
intoxication. Even though medical providers had knowl-
edge of SEB exposure in a subsequently hospitalized
patient involved in the June 1963 incident, the initial
symptoms of this patient still raised concern about a possi-
ble infectious cause. That patient was noted to have a
flushed face, mild hyperemia of the pharynx, a prominent
postnasal drip, a purulent-appearing otitis media and exter-
na without symptoms of ear pain, pulmonary symptoms
(productive cough and chest discomfort), and a leukocyto-
sis of 19,500 cells/mm3. Their differential diagnosis
included otitis externa and media, pneumonia, or SEB
intoxication. Otic examination was within normal limits 24
hours later, which suggested SEB as the possible cause of
the localized swelling. An infectious cause was also con-
sidered as the initial primary diagnosis in the initial two
patients with conjunctivitis in this series as the cause of the
conjunctivitis, gastrointestinal symptoms, or both, with
both persons receiving topical ophthalmic antimicrobial
agents for conjunctivitis. Healthcare workers evaluating
persons who work with SEB need to be aware of the full
spectrum of toxicity symptoms associated with SEB to
avoid misdiagnosis resulting in unnecessary treatment, to
identify breaches in laboratory technique, and to educate
persons at risk of the importance of personal protective
measures in preventing SEB exposure and intoxication.
These cases emphasize that personal protective measures
such as biosafety cabinets, gloves, and eye protection are
paramount when working with SEB. 
Dr. Rusnak is an active-duty officer in the U.S. Air Force
and a board-certified physician in infectious diseases. She is cur-
rently working as the deputy director of the Special
Immunizations Clinic of the Medical Division at the U.S. Army
Medical Research Institute of Infectious Diseases in Fort Detrick.
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